Enfortumab vedotin news

All news on Enfortumab vedotin (also known as Padcev): plants, production capacities, investments and involved companies.

10 July 2026

Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with Padcev for perioperative MIBC

FDA clears PD‑1 inhibitor plus antibody‑drug conjugate regimens with enfortumab vedotin as neoadjuvant and adjuvant therapy around cystectomy for adults with muscle‑invasive bladder cancer.
12 June 2026

Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with WELIREG for adjuvant ccRCC

FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.

Who will be producing Enfortumab vedotin in the future?

Find out with chemXplore

Learn more